None listed
Conditions
Interventions
None listed
Sponsors
Dongguk University Ilsan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) All adult patients (aged =18 years) (2) Microbiological evidence (sputum, urine, blood) of infection due to carbapenem-resistant Acinetobacter baumannii during hospitalization (3) Intravenous Colistimethate sodium treated patient with Acinetobacter baumannii infection who fulfill the above criteria (4) Patients who agree to the gathering clinical information by means of an informed consent
Exclusion criteria
Exclusion criteria: (1) Pregnancy and lactating women (2) Patients receiving Colistimethate sodium therapy for <48 hours (3) Patient of chronic renal disease defined as a Creatinine clearance <10 mL/min, Or requirement for peritoneal or hemo-dialysis or hemofiltration (4) Known hypersensitivity to Colistimethate sodium (5) Receiving intravenous colistin therapy within the past 30 days (6) Patients treated with nebulized Colistimethate sodium
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in plasma drug concentration between patients with nephrotoxicity and those without | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in plasma drug concentration between patients showing clinical cure or improvement and those of treatment failure;Difference in plasma drug concentration according to microbiological response;Difference in plasma drug concentration according to in-hospital mortality;Difference in plasma drug concentration according to the RIFLE Criteria for nephrotoxicity;Nephrotoxicity and associated factors;Other adverse effect: plasma drug concentration between patients with abnormality of liver function, thrombocytopenia and neurotoxicity | — |
Countries
Korea, Republic of
Contacts
Public ContactYoung-Soon Yoon
Dongguk University Ilsan Hospital
Outcome results
None listed